Haberman RH, Castillo R, Chen A, et al. - This study was intended to define the hospitalization and death rates among patients with inflammatory arthritis affected by COVID‐19 and to analyze the associations between comorbidities and immunomodulatory medications and infection outcomes. Researchers prospectively evaluated clinical, demographic, maintenance treatment, and disease course data and outcomes of individuals with inflammatory arthritis (IA; rheumatoid arthritis and spondylarthritis) with symptomatic COVID‐19 infection via web‐based questionnaire followed by individual phone calls and electronic medical record review. They summarized baseline characteristics and medication for hospitalized and ambulatory patients, and outcomes were correlated for each medication class applying multivariable logistic regression. They enrolled a sum of 103 patients with IA in the study (n=80 confirmed and n=23 highly suspicious for COVID‐19). The results revealed that COVID‐19 outcomes were worse in those receiving glucocorticoids but not in patients on maintenance anti‐cytokine therapy in patients with underlying IA. Future study is required to understand if immunomodulatory therapies affect COVID‐19 incidence.